ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0211

Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus

Sophia Lutgen1, S. Sam Lim2, Laura D. Aspey2, Gaobin Bao3, Charmayne Dunlop-Thomas2, Jessica N. Williams2 and Cristina Drenkard2, 1Mount Sinai Morningside-West, New York, NY, 2Emory University, Atlanta, GA, 3Emory University School of Medicine, Atlanta, GA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, COVID-19, Cutaneous, Disparities, race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they may be more hesitant to receive the COVID-19 vaccine. Black individuals have a higher susceptibility to chronic cutaneous lupus erythematosus (CCLE); however, these patients are underrepresented in COVID-19 studies. We studied vaccination and patients’ perceptions during the early pandemic period in a predominantly Black cohort of patients with CCLE.

Methods: Patients with a validated diagnosis of CCLE enrolled in the population-based Georgians Organized Against Lupus (GOAL) Cohort were surveyed early in the pandemic, January through August 2021, after COVID-19 vaccination was available in the U.S. Validated tools assessed vaccination perceptions and ad hoc questions assessed COVID-19 concerns and vaccine status. We studied the relationship between vaccination status and trusted sources, concerns, beliefs, and vaccination attitudes.

Results: Of 158 respondents (54% primary CCLE and 46% CCLE + SLE), 82% returned the survey by August 2021. Most participants were Black (81%) and female (89%), with a mean age of 54; 40% reported living below the Federal poverty level and 42% were unemployed. Although 76% did not receive the vaccine, 17% and 6% received 1 and 2 doses, respectively. The most frequent vaccination attitudes were concerns about unfound problems (79%), unknown future effects (69%), unforeseen problems in children (50%), followed by reliability (49%), protection (48%), and safety (47%) (Fig. 1). Participants were highly concerned about COVID-19 infection consequences (Fig. 2). Black participants (p=0.01), those living in poverty (p=0.006), and unemployed (p< 0.001) were less likely to be vaccinated (Table 1). Doctors were a trusted source in 71% of participants, of which 31% received the vaccine (p=0.001). Mistrust was significantly related to unvaccinated status (p< 0.001). Participants who believed that lupus patients should get vaccinated, that vaccines protect against infection, or those that would get the vaccine regardless of a doctor’s advice were more likely to be vaccinated (p< 0.001 for each); whereas those who believed the vaccine will cause lupus to flare (p=0.001), interacts with medications and causes harm (p=0.004), or is less effective in lupus patients than in the general population (p=0.007) were less likely to be vaccinated.

Conclusion: In the early pandemic period, only 23% of patients with CCLE were COVID-19 vaccinated. Participants who were Black, living in poverty, or unemployed were less likely to be vaccinated. Concerns about COVID-19 infection were not associated with vaccine status; whereas mistrust and negative beliefs of vaccine benefits were more likely to occur among those unvaccinated. Despite that 71% participants trusted their doctors, only 31% received the vaccine. Longitudinal studies are needed to assess changes in perceptions and vaccination rates. Education interventions are critical to mitigate vaccine hesitancy in CCLE patients, particularly among those of Black race and socioeconomically disadvantaged.

Supporting image 1

Figure 1. Vaccination Attitudes among 158 participants of a population-based cohort with a validated diagnosis of CCLE. Vaccination attitudes were measured with the Examination (VAX) Scale.

Supporting image 2

Figure 2. COVID_19 infection concerns reported by 158 participants of a population-based cohort with a validated diagnosis of CCLE.

Supporting image 3

Table. Factors Associated with COVID_19 Vaccination among Patients with Chronic Cutaneous Lupus Erythematosus.


Disclosures: S. Lutgen, None; S. Lim, None; L. D. Aspey, None; G. Bao, None; C. Dunlop-Thomas, None; J. Williams, None; C. Drenkard, None.

To cite this abstract in AMA style:

Lutgen S, Lim S, D. Aspey L, Bao G, Dunlop-Thomas C, Williams J, Drenkard C. Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/determinants-of-covid-19-vaccine-hesitancy-in-a-predominantly-black-population-with-cutaneous-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/determinants-of-covid-19-vaccine-hesitancy-in-a-predominantly-black-population-with-cutaneous-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology